☆ 3.9 Article

Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

BLOOD CANCER DISCOVERY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma

Radhika Bansal et al.

Summary: Bone marrow assessment of minimal residual disease (MRD) is a prognostic factor for survival in multiple myeloma (MM). The value of MRD-negative (MRDneg) status at month 1 after CAR-T treatment is still unclear. This study examined the impact of month 1 bone marrow MRD status in MM patients who received CAR-T therapy at Mayo Clinic. The results showed that MRDneg status at month 1 was associated with prolonged survival, and the evaluation of bone marrow early post-CAR-T infusion could be a prognostic tool.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Hematology

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

Noemi Puig et al.

Summary: Monitoring of M-protein by EXENT&FLC-MS is more sensitive and accurate compared to IFE, providing better prediction of patients' outcome in MM.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

MRD in multiple myeloma: does CR really matter?

Bruno Paiva et al.

Summary: Multiple myeloma survival is longer with deeper response, but there are conflicting results regarding complete remission and minimal residual disease negativity. Some patients with persistent M protein have undetectable MRD. We reviewed the frequency of this discrepancy and suggest MRD assessment for patients achieving very good partial response or better.

BLOOD (2022)

Add to Collection

Article Hematology

Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma

David Boeckle et al.

Summary: Combining NGF with imaging can be helpful in heavily pretreated multiple myeloma patients, and MRD-based consolidation can lead to improved progression-free survival.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Education, Scientific Disciplines

Cellular therapy for multiple myeloma: what's now and what's next

Paula Rodriguez-Otero et al.

Summary: This review discusses the recent advances in BCMA-directed CAR T-cell therapy in relapsed and refractory multiple myeloma (RRMM), as well as potential future developments focused on optimizing patient care and novel CAR designs.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)

Add to Collection

Article Hematology

MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials

Bruno Paiva et al.

BLOOD (2022)

Add to Collection

Article Hematology

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Hartmut Goldschmidt et al.

Lancet Haematology (2022)

Add to Collection

Meeting Abstract Hematology

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C. Munshi et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow

Laura Notarfranchi et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation AntigenDirected Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin et al.

BLOOD (2021)

Add to Collection

Article Oncology

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Herve Avet-Loiseau et al.

Summary: In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by more than 60% in the POLLUX and CASTOR trials. The use of daratumumab-based combinations resulted in higher rates of sustained MRD negativity compared to standard of care, leading to improved clinical outcomes and prolonged progression-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma

Noemi Puig et al.

Summary: Our study supports the routine assessment of bone marrow cellularity to evaluate hemodilution, using treatment-specific or healthy adult reference values to indicate potential false-negative minimal residual disease results.

CANCERS (2021)

Add to Collection

Article Hematology

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Ana Jimenez-Ubieto et al.

BLOOD (2021)

Add to Collection

Article Medicine, General & Internal

Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesus G. Berdeja et al.

Summary: The study aimed to evaluate the safety and clinical activity of cilta-cel in patients with relapsed or refractory multiple myeloma, and the results showed that cilta-cel treatment achieved good efficacy and safety with short treatment duration, deep response, and long duration of response.

LANCET (2021)

Add to Collection

Article Oncology

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

Bruno Paiva et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Nikhil C. Munshi et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Oncology

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Alejandro Medina et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Article Medicine, General & Internal

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau et al.

LANCET (2019)

Add to Collection

Article Hematology

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot et al.

BLOOD (2018)

Add to Collection

Article Oncology

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

J. Flores-Montero et al.

LEUKEMIA (2017)

Add to Collection

Review Oncology

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar et al.

LANCET ONCOLOGY (2016)

Add to Collection

Review Hematology

New criteria for response assessment: role of minimal residual disease in multiple myeloma

Bruno Paiva et al.

BLOOD (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.